

Special Issue

Clinical Development in Multiple Sclerosis Diagnosis and Treatment

Message from the Guest Editor

Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease that continues to challenge clinicians and researchers alike. Recent years have seen a surge in our understanding of the pathogenesis and treatment options for MS, yet there is still much to be uncovered. The application of humoral, clinical, or digital biomarkers to detect early onset or monitor disease progression has become commonplace. A biomarker precisely reflecting the inflammatory and degenerative components of MS would allow for therapies to be exactly adapted, reducing delays in treatment optimization. The call for robust molecular and cellular biomarkers to evaluate MS therapies is more urgent than ever. This Special Issue focuses on enhancing our understanding and advancing the field of MS through innovative research on biomarkers. We are inviting original research articles and reviews that explore: Pharmacogenomics and Proteomics in MS, Systems Biology in MS, Omics Association Analysis in MS and Clinical Development of MS Biomarkers.

Dr. Majid Ghareghan

Guest Editor

Dr. Majid Ghareghani

Neuroscience Laboratory, CHU de Québec Research Centre, Department of Molecular Medicine, Faculty of Medicine, Laval University, Québec City, QC G1V 4G2, Canada

Deadline for manuscript submissions

closed (31 January 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/174359

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).